Enhancing Oxygen,
Fueling Life
Targeting Treatments for Hypoxia
Learn more

Improving Oxygen Availability

Novel Mechanism of Action

Lead drug trans sodium crocetinate (TSC) enhances the oxygen diffusion process, supporting normal, physiologic levels of oxygen diffusion at uptake and delivery.

Selective for Hypoxic Tissue

In animal models, TSC’s mechanism of action enhanced oxygen availability to hypoxic tissue without oversupplying normoxic tissue.

Demonstrated Safety Profile

TSC has been safe and well tolerated in over 200 subjects dosed in prior preclinical and clinical studies.

OUR PIPELINE

Potential Treatment for
Hypoxia-related Indications

Diffusion Pharmaceuticals is actively evaluating the clinical effects of TSC on oxygenation and hypoxia-related indications, building upon data from prior clinical studies in peripheral artery disease, glioblastoma multiform (GBM) brain cancer, stroke, and COVID-19.

Learn more

News

The latest news, press releases, and more.

Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study

 Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., March 25, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Doses First Participants in TCOM Study

 Diffusion Pharmaceuticals Doses First Participants in TCOM Study 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., March 18, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Reports 2020 Financial Results and Provides Business Update

 Diffusion Pharmaceuticals Reports 2020 Financial Results and Provides Business Update 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., March 17, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares of Common Stock

 Diffusion Pharmaceuticals Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares of Common Stock 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., February 18, 2021 — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock

 Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., February 17, 2021 — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients

 Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Feb. 16, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference

 Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE)

Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates

 Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Nov. 12, 2020 (GLOBE NEWSWIRE)

Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer

 Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va. (October 19, 2020) – Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Strengthens Management Team with Appointment of William Elder as General Counsel and Corporate Secretary

 Diffusion Pharmaceuticals Strengthens Management Team with Appointment of William Elder as General Counsel and Corporate Secretary 2560 1707 Diffusion Pharmaceuticals Inc.

CHARLOTTESVILLE, Va., Sept. 24, 2020 (GLOBE NEWSWIRE)

Back to top